An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MUNIN
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 26 Mar 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History